Giladi N - Search Results

1

Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis.

Agalliu I, San Luciano M, Mirelman A, Giladi N, Waro B, Aasly J, Inzelberg R, Hassin-Baer S, Friedman E, Ruiz-Martinez J, Marti-Masso JF, Orr-Urtreger A, Bressman S, Saunders-Pullman R. Agalliu I, et al. Among authors: giladi n. JAMA Neurol. 2015 Jan;72(1):58-65. doi: 10.1001/jamaneurol.2014.1973. JAMA Neurol. 2015. PMID: 25401981 Free PMC article.

2

Absence of mutations in ATM, the gene responsible for ataxia telangiectasia in patients with cerebellar ataxia.

Hassin-Baer S, Bar-Shira A, Gilad S, Galanty Y, Khosravi R, Lossos A, Giladi N, Weitz R, Ben-Zeev B, Goldhammer Y, Shiloh Y. Hassin-Baer S, et al. Among authors: giladi n. J Neurol. 1999 Aug;246(8):716-9. doi: 10.1007/s004150050438. J Neurol. 1999. PMID: 10460451 Clinical Trial.

3

The nigrostriatal dopaminergic system in familial early onset parkinsonism with parkin mutations.

Portman AT, Giladi N, Leenders KL, Maguire P, Veenma-van der Duin L, Swart J, Pruim J, Simon ES, Hassin-Baer S, Korczyn AD. Portman AT, et al. Among authors: giladi n. Neurology. 2001 Jun 26;56(12):1759-62. doi: 10.1212/wnl.56.12.1759. Neurology. 2001. PMID: 11425950

4

Gait disturbances in advanced stages of Parkinson's disease.

Giladi N. Giladi N. Adv Neurol. 2001;86:273-8. Adv Neurol. 2001. PMID: 11553986 Review. No abstract available.

5

Rasagiline mesylate, a new MAO-B inhibitor for the treatment of Parkinson's disease: a double-blind study as adjunctive therapy to levodopa.

Rabey JM, Sagi I, Huberman M, Melamed E, Korczyn A, Giladi N, Inzelberg R, Djaldetti R, Klein C, Berecz G; Rasagiline Study Group. Rabey JM, et al. Among authors: giladi n. Clin Neuropharmacol. 2000 Nov-Dec;23(6):324-30. doi: 10.1097/00002826-200011000-00005. Clin Neuropharmacol. 2000. PMID: 11575866 Clinical Trial.

6

Clinical characteristics of neuroleptic-induced parkinsonism.

Hassin-Baer S, Sirota P, Korczyn AD, Treves TA, Epstein B, Shabtai H, Martin T, Litvinjuk Y, Giladi N. Hassin-Baer S, et al. Among authors: giladi n. J Neural Transm (Vienna). 2001;108(11):1299-308. doi: 10.1007/s007020100006. J Neural Transm (Vienna). 2001. PMID: 11768628

7

Pharmacokinetics of etilevodopa compared to levodopa in patients with Parkinson's disease: an open-label, randomized, crossover study.

Djaldetti R, Giladi N, Hassin-Baer S, Shabtai H, Melamed E. Djaldetti R, et al. Among authors: giladi n. Clin Neuropharmacol. 2003 Nov-Dec;26(6):322-6. doi: 10.1097/00002826-200311000-00012. Clin Neuropharmacol. 2003. PMID: 14646613 Clinical Trial.

8

Falls in outpatients with Parkinson's disease: frequency, impact and identifying factors.

Balash Y, Peretz C, Leibovich G, Herman T, Hausdorff JM, Giladi N. Balash Y, et al. Among authors: giladi n. J Neurol. 2005 Nov;252(11):1310-5. doi: 10.1007/s00415-005-0855-3. Epub 2005 May 18. J Neurol. 2005. PMID: 15895303

9

The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect?

Orr-Urtreger A, Shifrin C, Rozovski U, Rosner S, Bercovich D, Gurevich T, Yagev-More H, Bar-Shira A, Giladi N. Orr-Urtreger A, et al. Among authors: giladi n. Neurology. 2007 Oct 16;69(16):1595-602. doi: 10.1212/01.wnl.0000277637.33328.d8. Neurology. 2007. PMID: 17938369

10

Advances in the genetics of Parkinson's disease.

Rosner S, Giladi N, Orr-Urtreger A. Rosner S, et al. Among authors: giladi n. Acta Pharmacol Sin. 2008 Jan;29(1):21-34. doi: 10.1111/j.1745-7254.2008.00731.x. Acta Pharmacol Sin. 2008. PMID: 18158863 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

536 results

Search Page

Filters